TCM
NRIX icon

TCG Crossover Management’s Nurix Therapeutics NRIX Stock Holding History

TCG Crossover Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-717,654
Closed -$7.41M – 34
2023
Q4 		$7.41M Buy
+717,654
New +$4.92M 0.82% 25

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TCG Crossover Management's NRIX Position: Q1 2024 in Review

TCG Crossover Management sold out of Nurix Therapeutics (NRIX) in Q1 2024, closing a stake of 717,654 shares — an estimated $7.41M sold.

TCG Crossover Management first reported a position in NRIX in Q4 2023 and held it in 1 quarter. The position peaked at $7.41M in Q4 2023. 139 funds tracked by Wall St. Rank hold NRIX as of Q1 2024.

  • TCG Crossover Management reported no remaining Nurix Therapeutics position as of Q1 2024 after selling out during the quarter.
  • TCG Crossover Management sold 717,654 Nurix Therapeutics shares in Q1 2024, an estimated $7.41M.
  • TCG Crossover Management first reported a position in Nurix Therapeutics in Q4 2023 and held it in 1 quarter.
  • TCG Crossover Management's Nurix Therapeutics position peaked at $7.41M in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2024.

Based on TCG Crossover Management's 13F filing for Q1 2024, filed 15 May 2024.